evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

33 questions · 33 findings · 3 reviews · Lung Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 9.1%GRADE not reported 2 · 6.1%Very low 2 · 6.1%Low 17 · 51.5%Moderate 9 · 27.3%High 0 · 0%

Non‐platinum single‐agent vs non‐platinum combination treatment

Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Non‐platinum single‐agent vs non‐platinum combination treatment

Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · non‐small cell lung cancer in the elderly population

It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ thrombocytopenia compared with non‐platinum combination treatment (very low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall response rate (ORR), · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

QoL · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).

1 finding from 1 review

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer

Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).

1 finding from 1 review